As the NLRP3 inflammasome plays a vital role in PD progression, inhibitors of NLRP3 inflammatory pathways that may hamper NLRP3 inflammasome activation offer novel therapeutic avenues for PD therapy. This evidence concerns the gene NLRP3 and Parkinson disease.